Possibility and prospects of using bamlanivimab in patients with COVID-19


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Currently, there is insufficient scientific evidence to recommend the routine use of bamlanivimab for the treatment of outpatients with COVID-19. An interim analysis of the phase II randomized placebo-controlled BLAZE-1 trial demonstrates the potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19, and its effectiveness in preventing the development of COVID-19 among medical personnel and residents of nursing homes.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

K. Mirzaev

Russian Medical Academy of Continuous Professional Education

D. Sychev

Russian Medical Academy of Continuous Professional Education

Әдебиет тізімі

  1. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. Published November 9, 2020. (date of access: 22.12. 2020). URL: https://www.fda.gov/mvdia/143603/download
  2. Chen P, Nirula A., Heller B., et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N EnglJ Med. Published on-line October 28, 2020. Doi: W.W56/NEJMoa202984-9.
  3. National Institutes of Health (NIH) News Release. Statement - NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. Published October 26, 2020. (date of access: 22.12.2020). URL: https://www.niaid.nih.gov/news-events/ statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study.
  4. URL: https://www.covid19treatmentgu'idelines. nih.gov/statement-on-bamlanivimab-eua
  5. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (date of access: 28.12.2020). URL: https://www.idsociety.org/practice-guideline/ covid-19-guideline-treatment-and-management

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021